The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR)
bacteria, especially Gram-negative (G− ve) pathogens, is acknowledged as one of the …

There is growing global recognition that the continued emergence of multidrug-resistant
bacteria poses a serious threat to human health. Action plans released by the World Health …

Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors.
Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes …

Linezolid, the principal oxazolidinone antibiotic for therapy of Gram-positive infections, is
limited by its myelosuppression and monoamine oxidase (MAO) inhibition, with the latter …

Contezolid is a novel oxazolidinone, which exhibits potent activity against gram-positive
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin …

Contezolid, a new oxazolidinone antibacterial agent currently in development for the
treatment of skin and skin structure infections, was susceptibility tested against Gram …

An evaluation of the anti-Mycobacterium abscessus activity expressed by a novel
oxazolidinone, contezolid (MRX-I), toward 12 reference strains and 194 clinical isolates was …

The analysis of antimicrobial activity is usually MIC-and minimal bactericidal concentration
(MBC)-focused, though also crucial are resistance-related parameters, eg, the frequency of …

Contezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium
tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it …

Background Staphylococcus aureus has been well recognized as an important cause of
community-acquired pneumonia (CAP), with non-specific characteristics and poor …